biomodal

biomodal is a life-sciences technology and analytics company founded in 2012, based in the UK. The company specializes in developing advanced multiomics research tools that integrate genetic and epigenetic information from a single sample. Their flagship product, the duet multiomics solution, allows researchers to extract detailed epigenetic information from low input DNA libraries without the need for complex bioinformatics or harsh chemical treatments. The duet solution distinguishes between standard DNA bases and modified cytosine bases, which are crucial for research in cancer, neurodegenerative diseases, and aging. biomodal employs a single-base-resolution, phased sequencing approach that combines genetic and epigenetic data in one workflow, enhancing the accuracy and depth of biological insights. This technology is designed to simplify multiomic analysis, making it a valuable resource for life scientists and clinical developers.

Research Chester, United States ~13 employees Private ยท Series D

Work at biomodal in HR or recruiting? Claim this page

Employees
13
0% in the 3 months to Sep 2026
Total funding
$145M
Last round Series D, Nov 2021
12-month attrition
23.4%
Tech: 150%
H1B sponsor
NA

Headcount trend

biomodal went from 14 employees in Oct 2024 to 13 in Sep 2026. Apr to Sep 2026: 1 people joined, 1 left.

Funding rounds

Total funding$145M
Funding rounds4
Investors10

Org structure

Headcount by department

Other6
Sales3
Marketing3
Success1

biomodal FAQ

How many employees does biomodal have?

biomodal has about 13 employees, unchanged over the 3 months to Sep 2026.

How much funding has biomodal raised?

biomodal has raised $144.5M in total funding; its latest round was Series D in Nov 2021.

Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles.